- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00422357
Effect of Urtica Dioica on Glycemic Control in Patients With Type 2 Diabetes Mellitus
Diabetes mellitus is the most common metabolic disorder worldwide. Some herbs are traditionally used in treatment of type 2 diabetes mellitus (T2DM). Urtica Dioica (UD) or stinging nettle is traditionally used in Morocco, Turkey, Brasil, Jordan and with much frequency in northern Iran.
Studies on animal models along with in vitro studies has shown hypoglycemic effect for aqueous extract of UD.
This study aimed to investigate hypoglycemic effects of UD tea bags in patients with T2DM on glycemic control, insulin sensitivity, along with its effects on lipid profile (LP), blood pressure (BP), liver, and kidney function.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study will be performed under randomized, double-blind, placebo controlled, and case-control design. The object of this study is patients with T2DM. Patients are randomly assigned to start with placebo tea bags (3 tea bags as 2-gram tea bag steamed in boiling water for 20 minutes: mixture of bran powder which is already boiled in water twice plus spinach powder) in control groups and UD tea bags (3 tea bags as 2-gram tea bag steamed in boiling water for 20 minutes) in patients with T2DM for two months. Every two weeks, fasting glucose, postprandial glucose after a standard breakfast, serum insulin, lipids, alanine amino transferase (ALT), aspartate amino transferase (AST), creatinine (to calculate GFR), along with blood pressure will be measured.
To the best of our knowledge, this is the first Randomized Clinical Trial.
Study Type
Enrollment
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Mazandaran
-
Mahmood-Abaad, Mazandaran, Iran, Islamic Republic of
- Primary Health Care Office
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Clinical diagnosis of T2DM
- Must be able to drink UD or Placebo tea bags 3 times every day
Exclusion Criteria:
- Insulin dependent diabetes
- History of congestive heart failure within last 5 years (NYHA Class III-IV)
- History of significant pulmonary disease, myocardial infarction, cerebrovascular accident, or nephrotic syndrome within last 1 year
- Thyroid disease
- Known renal or hepatic insufficiency
- Gastric problem
- History of UD or and other herb use in past 6 months
- Pregnancy or lactation
- Use of any herbal or supplement within past 6 months
- Use of an investigational drug (within 30 days prior to enrollment)
- Known maternal allergies
- Dumping syndrome
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: FACTORIAL
- Masking: DOUBLE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Fasting blood glucose every two weeks.
|
Post prandial blood glucose every two weeks.
|
Fasting insulin every two weeks.
|
Insulin sensitivity as Quantitative Insulin Sensitivity Check Index (QUIKI) every two weeks.
|
C-Peptide every two weeks.
|
HBA1C every two weeks.
|
Serum lipids every two weeks.
|
Liver enzymes (ALT, AST) every two weeks.
|
GFR every two weeks.
|
Blood pressure every two weeks.
|
Collaborators and Investigators
Investigators
- Study Director: Navid Saadat, MD, Shaheed Beheshti Medical Univrsity
Study record dates
Study Major Dates
Study Start
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NNFTRI-1385
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
AstraZenecaNot yet recruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on Urtica Dioica (Tea bag)
-
Taipei Veterans General Hospital, TaiwanEnrolling by invitationHerbal InteractionTaiwan
-
Hong Kong Baptist UniversityThe Hong Kong Jockey Club Charities TrustCompletedCommon Cold | Preventive Effectiveness | Elderly With Qi-deficiency Constitution | The Individualized Jade Wind-Barrier Herbal Tea Bag | Pragmatic Randomized Controlled TrialChina
-
Chiayi Christian HospitalCompletedGestational Diabetes MellitusTaiwan
-
University of Alabama at BirminghamCongressionally Directed Medical Research ProgramsCompleted